文献速递神经肿瘤神经重症

死后弥漫性中线胶质瘤单核 profiling 揭示线粒体生物发生为 imipridone 耐药机制

Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapy.
PubMed 文献 · Neuro Oncol · 2026-01-01

本研究对接受 imipridone 和/或标准治疗的 DMG 患者死后脑组织进行单核 RNA 与开放染色质测序(N=22)、髓系免疫荧光表型分析(N=46)及线粒体拷贝数分析(N=19)。耐药肿瘤线粒体密度、周转和膜电位增加,线粒体生物发生与 PPARGC1A 成为耐药生物标志物及可干预靶点,抑制线粒体生物发生可增强 imipridone 疗效。

要点

  • imipridone 治疗可逆转 DMG 间质转化、减少髓系抑制细胞并逆转异常 H3K27 增强子活性。
  • 耐药肿瘤线粒体密度、周转及膜电位升高,线粒体生物发生和 PPARGC1A 为耐药标志。
  • 抑制线粒体生物发生可增强 imipridone 敏感性,提示联合治疗策略。

核心结论

  • 线粒体生物发生是 imipridone 耐药的生物标志物和组合治疗开发靶点。

研究设计与样本

  • 研究获取接受 imipridone 和/或标准治疗的 DMG 患者死后脑组织,进行单核 RNA 与开放染色质测序(N=22)、髓系免疫荧光表型分析(N=46)和线粒体拷贝数分析(N=19),并在 DMG 原代细胞中验证。

主要发现

  • imipridone 治疗导致间质转化消退、髓系来源抑制细胞减少并逆转异常 H3K27 增强子活性。
  • 耐药肿瘤显示线粒体密度、周转和膜电位增加。
  • 线粒体生物发生和 PPARGC1A 成为耐药生物标志物及可干预靶点。

临床怎么用

  • 线粒体生物发生和 PPARGC1A 可作为 imipridone 耐药生物标志物。
  • 抑制线粒体生物发生与 imipridone 联用可能克服耐药。
  • imipridone 增强抗肿瘤免疫反应,可能与新兴免疫治疗协同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Imipridone ONC201 is the first FDA-approved therapy for H3K27-altered diffuse midline glioma; however, clinical responses remain limited. Defining tumor-intrinsic determinants and microenvironmental, extrinsic factors that shape sensitivity or resistance to imipridones will identify actionable therapeutic opportunities and inform improved clinical strategies. METHODS: To identify mechanisms of imipridone resistance, we obtained postmortem brain tissue from DMG patients who had received imipridones and/or standard care. Single-nucleus RNA and open-chromatin sequencing were performed on N = 22 cases. Immunofluorescence-based myeloid phenotyping was performed on N = 46 cases. Mitochondrial copy-number analysis was performed on N = 19 cases. Validation of imipridone sensitivity, its effect on mitochondrial density, and its synergy with inhibition of mitochondrial biogenesis were assessed in DMG primary cells. RESULTS: We established a single-cell RNA/open-chromatin atlas from postmortem DMG cases and found imipridone treatment resulting in regressed mesenchymal transition, reduced myeloid-derived suppressive cells, and reversed aberrant H3K27-altered enhancer activity. Resistant tumors showed increased mitochondrial density, turnover, and membrane potential. Mitochondrial biogenesis and PPARGC1A emerged as resistance biomarkers and actionable targets. CONCLUSIONS: These studies implicate mitochondrial biogenesis as a biomarker of imipridone resistance and a focus for the development of combinatorial strategies to provide effective therapeutic options for a challenging pediatric brain tumor. Diffuse midline gliomas are lethal brain tumors, mostly affecting children. The drug Dordaviprone was recently approved by the Food and Drug Administration as the first systemic therapy for this disease. However, it is not a cure. In this study, we asked why some patients stop responding to Dordaviprone and how we might overcome this resistance. By analyzing tumor samples from patients, we found that resistant tumors increase their number of mitochondria, structures that produce energy, helping them to survive treatment. Blocking this energy-producing process enhanced Dordaviprone’s effectiveness. Moreover, Dordaviprone enhanced anti-tumor immune responses and may thus synergize with emerging immunotherapies.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Okada M, Subramaniam B, Geng B, et al. Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapy. Neuro Oncol. 2026. PMID: 42178382. doi:10.1093/neuonc/noag119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。